Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma

Trial Profile

ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Aug 2018

At a glance

  • Drugs Sorafenib (Primary) ; Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms ASSURE
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 18 Aug 2018 Results of a retrospective subgroup analysis of this study, published in the Journal of Urology.
    • 05 Jun 2018 Results of a retrospective subgroup analysis of this study, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top